Groton biotech firm working on much-needed drug to treat stroke, brain injuries

2 Dec 2021

Community Interest, Economic Development

A small drug development company that moved its headquarters from Cambridge, Mass., to the BioCT Innovations Commons on Shennecossett Road last year is aiming to have a huge impact on the treatment of strokes and brain injuries.

Co-founded by William Korinek of Stonington, who spent nearly a decade at Pfizer, Astrocyte Pharmaceuticals expects to launch a phase one clinical trial of its leading drug candidate in the first half of 2022. Last week, Astrocyte put out word that Stroke, a peer-reviewed journal, had published the results of preclinical studies of the drug, known for now as AST-004.

Click here for the full article